Abstract
Gallic acid (3,4,5-trihydroxybenzoic acid) a plant phenolic antioxidant is known for its strong antiinflammatory, anti-mutagenic and anti-carcinogenic activities. But due to a lower half-life and rapid clearance by the body, frequent administration of the molecule is required. To improve the bioavailability and prolong its duration in the body system, its phospholipid complex was prepared and evaluated for various physico-chemical parameters like encapsulation efficiency, scanning electron microscopy, differential scanning calorimetry, X-ray powder diffractometry, IR spectroscopy and dissolution study. The phospholipid complex of gallic acid (Ga-Pc) was found to be fluffy and porous with rough surface morphology. FTIR, DSC and XRPD data confirmed the complex formation. The 89.1% of gallic acid was encapsulated in the phospholipid complex. A controlled release pattern was shown by the complex (which showed continuous release up to 93% of gallic acid) at the end of 24 h in comparison to free gallic acid (which showed 81.91% burst release just in the 0.5 h).
Keywords: Gallic acid, Phosphatidylcholine, Controlled release, Encapsulation, DSC, X-RPD
Letters in Drug Design & Discovery
Title: Gallic Acid-Phospholipid Complex: Drug Incorporation and Physicochemical Characterization
Volume: 8 Issue: 3
Author(s): Devendra Singh, Mohan Singh Maniyari Rawat, Ajay Semalty and Mona Semalty
Affiliation:
Keywords: Gallic acid, Phosphatidylcholine, Controlled release, Encapsulation, DSC, X-RPD
Abstract: Gallic acid (3,4,5-trihydroxybenzoic acid) a plant phenolic antioxidant is known for its strong antiinflammatory, anti-mutagenic and anti-carcinogenic activities. But due to a lower half-life and rapid clearance by the body, frequent administration of the molecule is required. To improve the bioavailability and prolong its duration in the body system, its phospholipid complex was prepared and evaluated for various physico-chemical parameters like encapsulation efficiency, scanning electron microscopy, differential scanning calorimetry, X-ray powder diffractometry, IR spectroscopy and dissolution study. The phospholipid complex of gallic acid (Ga-Pc) was found to be fluffy and porous with rough surface morphology. FTIR, DSC and XRPD data confirmed the complex formation. The 89.1% of gallic acid was encapsulated in the phospholipid complex. A controlled release pattern was shown by the complex (which showed continuous release up to 93% of gallic acid) at the end of 24 h in comparison to free gallic acid (which showed 81.91% burst release just in the 0.5 h).
Export Options
About this article
Cite this article as:
Singh Devendra, Singh Maniyari Rawat Mohan, Semalty Ajay and Semalty Mona, Gallic Acid-Phospholipid Complex: Drug Incorporation and Physicochemical Characterization, Letters in Drug Design & Discovery 2011; 8 (3) . https://dx.doi.org/10.2174/157018011794578240
DOI https://dx.doi.org/10.2174/157018011794578240 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methotrexate: Should We Start Using it in Clinical Practice?
Current Drug Targets Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer
Current Computer-Aided Drug Design Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Targeted Photodynamic Therapy (PDT) of Lung Cancer with Biotinylated Silicon (IV) Phthalocyanine
Current Pharmaceutical Biotechnology Vascular microRNAs
Current Drug Targets Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Current Cancer Therapy Reviews Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation
Current Pharmaceutical Design A Potential Anticancer Agent 1,2-di(quinazolin-4-yl)diselane
Letters in Drug Design & Discovery The Bcl-2 Family as a Rational Target for the Treatment of B-Cell Chronic Lymphocytic Leukaemia
Current Medicinal Chemistry Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma
Letters in Drug Design & Discovery Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design Surface Plasmon Resonance Imaging (SPRI) Sensor for Cystatin Determination Based on Immobilized Papain
Protein & Peptide Letters miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion
Current Molecular Medicine Preparation and Surface Modification of Polymeric Nanoparticles for Drug Delivery: State of the Art
Recent Patents on Drug Delivery & Formulation VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry